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In recent years a rising amount of randomized controlled trials, reviews, and meta-analyses
relating to the efficacy of electroencephalographic-neurofeedback (EEG-NF) in children
with attention-deficit/hyperactivity disorder (ADHD) have been published. Although clinical
reports and open treatment studies suggest EEG-NF to be effective, double blind
placebo-controlled studies as well as a rigorous meta-analysis failed to find support for
the efficacy of EEG-NF. Since absence of evidence does not equate with evidence of
absence, we will outline how future research might overcome the present methodological
limitations. To provide conclusive evidence for the presence or absence of the efficacy of
EEG-NF in the treatment of ADHD, there is a need to set up a well-designed study that
ensures optimal implementation and embedding of the training, and possibly incorporates
different forms of neurofeedback.
Keywords: EEG-neurofeedback (EEG-NF), attention-deficit/hyperactivity disorder (ADHD), efficacy, methodology,
non-pharmacological interventions
Attention-deficit/hyperactivity disorder (ADHD) is the most
common neurodevelopmental disorder, affecting about 5% of
all children worldwide. ADHD is characterized by a pattern of
inattention and/or hyperactivity and impulsivity (Polanczyk et al.,
2007).
While medication is the most effective treatment in ADHD
(Faraone and Buitelaar, 2010), it also entails a number of con-
cerns. Firstly, side effects have been reported and for some seri-
ous and life-threatening side effects, the risk is not clear and
will likely remain so due to the rarity of these events (Graham
et al., 2011). Children with ADHD and their parents also have
significant reservations about possible negative long-term effects
of medication (Berger et al., 2008). Secondly, there is insufficient
evidence of long-term efficacy of medication for ADHD (van
de Loo-Neus et al., 2011). Thirdly, the symptoms of ADHD
have been found to reappear after discontinuing drug treatment
(Jensen et al., 2007; Murray et al., 2008). These misgivings
about ADHD medications have contributed to the interest in
developing non-pharmacological approaches to treatment, such
as electroencephalographic-neurofeedback (EEG-NF). EEG-NF is
based on the rationales that (1) the neural basis of ADHD is
characterized by deviant EEG patterns that play a role in the
pathophysiology of the disorder; and (2) voluntary modulation
of specific brain activity patterns can be learned by operant
learning strategies. The first rationale originates from the finding
that the majority of resting state electroencephalography (EEG)
in children with ADHD is characterized by increased slow-wave
activity (primarily in theta range) and decreased fast-wave activ-
ity (primarily in beta range). These slow and fast waves are
often coupled, resulting in elevated theta/alpha and theta/beta
ratios (see Barry et al., 2003 for a review). Although a deviant
theta/beta ratio has been found in ADHD rather consistently
(Arns et al., 2013), the exact role of such a deviant pattern in
the pathophysiology of ADHD is not clear yet (van Dongen-
Boomsma, 2014). In addition, although voluntary modulation of
specific brain activity patterns might be possible, clear-cut proof
is still lacking. If these rationales are correct, they will provide
for a rational neuroscience-based treatment of ADHD that brings
about normalization of the underlying neural abnormality and
thereby clinical improvement.
EEG-NF; THE CURRENT STATE OF AFFAIRS
In recent years, a number of randomized controlled trials, reviews,
and meta-analyses relating to EEG-NF in children with ADHD
have been published. Although particularly non-blinded studies
conclude that EEG-NF is probably effective, robust evidence
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based on methodologically sound studies is still lacking. The
majority of studies did not include a placebo group and/or
blinded measures. Studies that did include a placebo group or
a blinded design have not found superior effects of EEG-NF
compared to placebo-NF (Perreau-Linck et al., 2010; Arnold
et al., 2012; van Dongen-Boomsma et al., 20131). In addition,
a systematic review and meta-analysis of randomized controlled
trials (RCTs) of non-pharmacological interventions in children
with ADHD including EEG-NF studies, reported non-significant
results for the blind rating of symptoms (ES 0.29, p = 0.07;
CI = −0.02, 0.61) (Sonuga-Barke et al., 2013). One of our
previous studies (Vollebregt et al., 2013) did not find any effects
at a neurocognitive level following EEG-NF treatment of ADHD
participants. This paper also included a systematic review of the
extant literature which indicated that our findings were in line
previous studies.
However, absence of evidence does not equate with evidence
of absence. If EEG-NF truly has no effect, then the possibility of
regulating brain activity via EEG-NF to improve ADHD symp-
toms can be refuted. Alternatively, a true effect of EEG-NF may
be hidden by methodological flaws which would imply that the
optimal way to apply or study this therapy is not yet known.
Improvements in a number of different areas will be needed
to overcome discrepancies in the EEG-NF literature. Firstly,
improvements will be needed in study-design. Secondly, the
implementation and embedding of the training may have to
be improved. Thirdly, the assessment of other forms of neu-
rofeedback, alongside EEG will also help to clarify outstanding
questions. These three levels of recommendations will be dis-
cussed below.
STUDY-DESIGN
While placebo-controlled RCTs are the gold standard in pharma-
cological research, there is no consensus regarding the optimal
design for EEG-NF experiments.
PLACEBO-CONTROLLED RCT’S
A major advantage of the inclusion of a placebo condition is that
all aspects of both treatments are identical except for the underly-
ing hypothesized working element. This enables allocation of pos-
itive findings to the working element only. Another advantage is
that the amount of expectancy is equal between groups in contrast
to all other control condition options, in which an equal amount
of expectancy is difficult or even impossible to assess and correct
for. The inclusion of a placebo condition also allows blindness of
the child and parents, making blind assessments by proximal indi-
viduals possible. A common misconception of placebo-controlled
RCTs which also exists in EEG-NF research (e.g., Heinrich et al.,
2007; Gevensleben et al., 2012) is that it would be unethical
to deprive participants of an effective treatment by allocating
them to the placebo condition instead of the treatment condition.
1The study by van Dongen-Boomsma et al. (2013) describes behavioral
data acquired from a project registered in the Clinical trial register under
“Project ADHD and EEG-Neurofeedback THERapy”; www.clinicaltrials.gov;
NCT00723684. Lansbergen et al. (2011) describe the pilot data of this project.
Vollebregt et al. (2013) describe the neurocognitive data of this project and in
addition provide a systematic review.
However, in cases where the efficacy of a treatment is not known
and the purpose of the study is to determine if the treatment may
be effective, then allocation of participants to a placebo group
does not involve depriving a participant of treatment, as long
as medication which a participant may be taking for his or her
condition is continued during the course of the experiment.
A randomized placebo-controlled trial also has drawbacks,
namely the fact that it is time- and energy- intensive, expensive,
and may not be the strongest design for all interventions or
settings (West and Spring, 2014).
Applying a randomized placebo-controlled trial design to
EEG-NF experiments might create a selection bias. In certain
cases, placebo-controlled RCT’s may thereby limit the external
validity of the findings (West et al., 2008). Only people that
are willing to accept that they may be allocated to the placebo
group will participate in the study. However, this problem may
partly be alleviated by ensuring that participants that are tak-
ing medication continue their regime unaltered throughout the
duration of the study. In addition, including a placebo con-
dition may make it more difficult to recruit participants due
to a potential participant’s reluctance to receive the placebo
treatment. This can be (partially) overcome by conducting a
multi-site center study and allowing ADHD medication to be used
through the study period. Furthermore, lowering the expectancy
by the possibility of allocation to the placebo group may make
it more difficult for the treatment to have a positive effect of
the treatment (like neuroregulation) (Gevensleben et al., 2009).
In accordance, most participants of EEG-NF placebo-controlled
RCTs conducted until now seem to experience the treatment
as a placebo condition (Logemann et al., 2010; Lansbergen
et al., 2011; van Dongen-Boomsma et al., 2013; Vollebregt et al.,
2013). One might speculate that this absence of efficacy is
caused by reduced motivation of the participants or—on the
other hand—from flaws in the protocol. The feasibility of the
training should therefore be rated by evaluating EEG indices
during the sessions of both groups (i.e., learning curves), in
addition to measuring the guessing rate (i.e., how well parent
and child were able to guess to what group they were allo-
cated), as well as analyzing the differences between pre and post
quantitative EEG measurements. Until now, of the randomized
placebo-controlled trials, Vollebregt et al. was the only study that
evaluated EEG indices during the sessions and did not show any
learning effect.
Generally, a placebo condition is only justified if the condition
meets the following criteria. Firstly, the placebo condition must be
inert with no possibility that this treatment trains a measurable
physiological effect. This should be assessed by analyzing EEG
indices during the sessions in the placebo condition. Secondly,
all participants (i.e., the child, his/her parents, teacher(s)) as well
as all examiners (i.e., the raters, but also the EEG-NF therapist)
should be blinded. Due to technical restrictions in placebo-
controlled studies it has not been possible to blind the therapist
while implementing manual thresholding. However, the promis-
ing proposal by Kerson (2013) has overcome these restrictions
by creating a design in which real-time noise is superimposed
on the placebo data creating the illusion of real time EEG
recordings.
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ALTERNATIVES TO PLACEBO-CONTROLLED RCT’S
In relation to psychotherapy research, problems with the use of
placebo-conditions have been emphasized (Borkovec and Sibrave,
2005). Clinical trials which attempt to eliminate unspecific treat-
ment components by the use of placebo-conditions, might give
an inaccurate estimate of the clinical value of the treatment
if nonspecific variables (e.g., expectations) interact with active
treatment components. Jeopardizing treatment fidelity in such
a way might also happen in EEG-NF. All problems discussed in
relation to psychotherapy can certainly not readily be generalized
to the research of EEG-NF in which the target of training is
non-psychological in nature, in contrast to the psychological
target psychotherapy has. Nevertheless, internal validity should
not be readily assumed in either design. The external validity of
alternatives to placebo-controlled RCT is often stronger than of
placebo-controlled RCTs, but they also face a serious limitation in
terms of ensuring internal validity (West et al., 2008). A number of
promising alternatives to placebo-controlled RCTs, which attempt
to overcome these difficulties, do exist. Disadvantages of perform-
ing a placebo-controlled RCT in certain situations and possible
solutions to deal with them were elaborately discussed by West
and Spring (2014). Their points and arguments on alternatives to
placebo-controlled RCT’s will be used further to discuss the use
of such alternatives to study EEG-NF. When studying EEG-NF,
the placebo condition can for instance be replaced with “additive
comparison” or “treatment dismantling” in which aspects that
are hypothesized to contribute to the efficacy of the treatment
are added or left out of the treatment respectively. Alternatives to
random assignment could be time-series, counterbalanced, cross-
over and group randomized designs. These alternatives avoid
unfair allocation and thereby circumvent a selection bias. “Partial
blinding” is a method which allows for manual thresholding while
minimizing the number of people that have to be unblinded.
Another option is an “equipoise design” in which two treatments
are equally well valued at the onset of the study which makes
blinding less relevant.
A concrete example of an alternative approach to a placebo-
controlled RCT for EEG-NF is “interrupted time series analysis”
in which the treatment is introduced at different time points, but
endpoints are equal (West et al., 2008). If the rater is unaware of
the duration of treatment, the measurement can still be blind and
expectancies of parents and children are controlled relatively well,
i.e., they all receive the treatment that they expect to be effective.
This design allows blind measures and comparable expectations
in each group despite the lack of a placebo group. However, the
design does assume that the amount of time spent on the training
predicts the amount of improvement.
THE OPTIMAL DESIGN
Regardless of the manner in which internal validity is maximized,
the study design can also be improved in other areas. For instance,
the sample size should be in congruence with the power analysis,
thereby enhancing the power and allowing more analyses (such
as subtype analyses). In addition, the study-design should seek to
determine whether or not EEG-NF is efficacious as a monother-
apy or alternatively is valuable as an add-on therapy received in
conjunction with medication. Although few studies to date have
compared medication to neurofeedback (Duric et al., 2012; Meisel
et al., 2013; Ogrim and Hestad, 2013), these studies struggled with
major limitations and inconsistent findings. A more thorough
comparison between medication and EEG-NF can be achieved by
including additional subgroups that assess participants without
medication together with participants on medication. A strong
design should furthermore obtain objective measures of ADHD
symptoms, e.g., by using school observations by an independent
observer, actometers, or neurocognitive tests. Finally, a strong
design should have an optimal implementation and embedding
of the treatment, discussed further below.
In summary, an improved design can be achieved by address-
ing the above mentioned points either through a placebo con-
trolled RCT or an alternative design. Importantly, a design can
only be optimal if reliable and valid outcome measures are
selected and good quality control is maintained throughout data
collection. Internal validity should be maximized while bias
should be minimized (West and Spring, 2014).
IMPLEMENTATION AND EMBEDDING OF THE TRAINING
EEG DEVIATION
Most EEG-NF protocols focus on ADHD-related deviation in
frequency bands during rest; up-regulation of theta power and
down-regulation of beta power (Monastra et al., 2005). While the
majority of children with ADHD exhibit diminished beta-power,
a subgroup of children with ADHD have been found to have
excessive beta-power (Arns, 2012). Thus, the idea of repairing a
deviate EEG pattern would not apply on these children without a
personalized protocol.
REWARD FEEDBACK
The percentage positive feedback that should be given has been
under debate. Some researchers argue that for instance 80%
positive feedback would to be too high for optimal learning (Arns
et al., 2014). The percentage should not be too high not allowing
sufficient learning, neither should the percentage be too low
preventing a feeling of control. Consensus on what this percentage
should be has not been reached and should be investigated.
LEARNING PARADIGMS
To further improve the training, the development of a paradigm
with instructions that are clearly goal-directed and in which the
participant is encouraged to actively attempt to reach a certain
“brain-state” might be more effective than strictly following an
operant learning principle in which learning occurs through
performance rather than through following a preceding intention.
Creating awareness of the desired behavior might not only be
more effective during training itself, but might also facilitate
transfer into daily life since the participant is actively aware how
to achieve a goal. Achievement of explicit goals might in addition
enhance motivation. Since no placebo-controlled studies until
now have been able to show specific treatment effects, a possible
explanation besides design-related explanations discussed above,
could be that a paradigm lacking clear instructions might not
lead to a learned behavior being able to be incorporated in a
participant’s daily life.
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TRANSFER
Without transfer of the (during treatment) learned skills into daily
life, the usefulness of EEG-NF can seriously be questioned. To
facilitate potential transfer effects into daily life, the following rec-
ommendations can be made. Explicit feedback on the deviation
of oscillations might enable awareness of how to minimize this
deviation, thereby creating a possibility to consciously prompt
this minimization in any situation in daily life as well. This could
be further strengthened by implementing transfer trials; a block
within the training in which no immediate feedback is given. The
participant is required to act as if immediate feedback is given at
that moment, even though feedback is only given after the block
has ended. In this way a daily life situation, in which no immediate
feedback is provided either, is simulated more realistically. The
implementation of transfer trials has already been applied (e.g.,
Strehl et al., 2006; Drechsler et al., 2007; Heinrich et al., 2007;
Leins et al., 2007; Gevensleben et al., 2009, 2014), but has not
been studied in a sufficiently well designed trial. Finally, transfer
effects can be optimized by combining the pure EEG-NF sessions
with sessions including behavioral therapeutic aspects to teach
the participant to recognize daily life situations in which to apply
the new skills learned from the EEG-NF (Heinrich et al., 2007;
Gevensleben et al., 2009). Despite different aspects of EEG-NF
that have been under debate as discussed above, a clear consensus
of how the optimal implementation of EEG-NF should look like
has not been reached.
DIFFERENT FORMS OF NEUROFEEDBACK
Of course, the conventional EEG-NF is not the only alternative
treatment for ADHD that could be studied. Different methods
than the most popular most practiced resting state oscillatory
EEG-NF could be scrutinized. Examples are online tomographic
NF (tNF) computed from multichannel scalp EEG (Liechti et al.,
2012), real-time functional magnetic resonance imaging neuro-
feedback (fMRI-NF) (Sulzer et al., 2013) or magnetoencephalo-
graphic neurofeedback (MEG-NF) (Foldes et al., 2011). The
advantage of tNF is that more specific brain regions can be
targeted due to the use of more electrodes. At least the same
advantage can be reached when using MEG, without all the
preparatory hustle that usually comes along with EEG. fMRI is
of course spatially even more precise but deals with a temporal
delay of measurement. Both MEG and fMRI based neurofeedback
are far more expensive than EEG; however difference in costs may
be less when only a few sessions are needed. Studies have shown
that all these methods are feasible, each having its own advantages
and disadvantages. All these methods seem to outperform con-
ventional EEG-NF since they allow more direct feedback, based
on more specific brain structures.
When sticking to the EEG-NF protocol or more specifically
to a personalized EEG-NF protocol, it can be questioned how
deviations should be determined. Children in the active group
of our study received a personalized protocol, but EEG data
recorded during the sessions showed that not all desired train-
ing directions were met (Vollebregt et al., 2013). Significant
improvement on group level can only solidly be interpreted if
all training conditions hypothesized to improve ADHD (either
on behavioral or neurocognitive level) are actually improved
in the desired direction. Determining deviations during rest
might differ from deviations during task performance. Gener-
alization to daily life might be greater when the neurofeedback
is based on EEG deviations during task performance. The most
often replicated EEG-deviation in ADHD has been shown at
rest (Arns et al., 2013), but does not show an unambiguous
relationship with behavioral and cognitive performance (van
Dongen-Boomsma, 2014). Still, the existence of a straightforward
relationship between these two is the basis of the conventional
EEG-NF therapy. Since dysfunction due to the core ADHD-
symptoms is primarly experienced during cognitive or motor
activity, a focus on electrophysiological indices during activ-
ity may have a better rationale than during rest. In addition,
generalization to daily life (hence, transfer) might be greater
when the neurofeedback is based on EEG deviations during
task performance. These arguments plead for real-time deviation
determined during interactive task performance. A clear example
of such an application of neurofeedback (in healthy individuals)
is by real-time training alpha oscillations during task performance
in an MEG scanner (e.g., Jensen et al., 2011).
In the early days, alpha enhancement neurofeedback
(6–13 Hz) protocols failed to find a specific effect on hyperkinetic
behavior (Nall, 1973). After this starting point, the alpha
frequency band has not been the focus of neurofeedback.
Nevertheless, alpha activity is associated with active inhibition
of brain areas, which is hypothesized to result in allocation
of attention (Klimesch et al., 2007). Aberrant modulation of
alpha activity during task performance has been associated with
attention problems on clinical level (i.e., adults with ADHD)
(ter Huurne et al., 2013). Hence, a relationship has actually
been shown between behavioral measures (to what extent the
cue induced allocation of attention) and alpha oscillations (the
lateralized difference in alpha power expected due to allocation of
attention following the inhibition notion) in ADHD. In addition,
the height of the alpha frequency peak has been shown to be lower
in a subgroup of children with ADHD (Vollebregt et al., in press)
and predictive to treatment outcome of several treatments (Ulrich
et al., 1984; Arns et al., 2008, 2009, 2012; Arns, 2012). Different
characteristics of the alpha frequency band therefore seem to
be relevant to ADHD. It is worthwhile to further investigate
neurofeedback possibilities training this frequency band. These
results could be related to the neurophysiological substrate of
the disorder. To study this active inhibition notion, active task
involvement is necessary implying interactive task performance.
By improving the therapy with suggestions mentioned above,
other forms of neurofeedback might also have potential as
treatment for ADHD.
CONCLUSION
The debate whether EEG-NF is an effective treatment for ADHD
can be closed by setting up an optimal study with a study-
design that tackles the drawbacks of a randomized placebo-
controlled trial design that are consequential to studying EEG-NF
while keeping blind measurements and avoiding other ways of
desecrating the internal validity. In addition, EEG-NF should
be implemented in an optimal learning setting both on the
technical level of the EEG-NF and with respect to embedding of
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the learning strategies into daily life. Finally, alternative forms of
neurofeedback to conventional EEG-NF, may offer other, maybe
even better, promising alternatives.
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